Trials / Completed
CompletedNCT04157621
taVNS in Mild to Moderate Parkinson's Disease
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Mild to Moderate Parkinson's Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 40 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether a non-invasive form of nerve stimulation called transcutaneous vagus nerve stimulation (taVNS) is safe and effective in people with Parkinson's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Active taVNS | Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus |
| DEVICE | Sham Stimulation | Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation. |
Timeline
- Start date
- 2018-03-20
- Primary completion
- 2021-06-15
- Completion
- 2021-06-15
- First posted
- 2019-11-08
- Last updated
- 2023-01-25
- Results posted
- 2023-01-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04157621. Inclusion in this directory is not an endorsement.